Clinical studies show thymosin alpha-1 reduced mortality, improved immune function, and decreased secondary infections in sepsis patients, though better patient selection is needed for future trials.
Reduced mortality + fewer secondary infectionsThymosin alpha-1 improved multiple clinical outcomes in sepsis by restoring immune competence rather than suppressing inflammation
What the researchers found
Across the reviewed clinical studies, thymosin alpha-1 treatment — both alone and in combination with anti-inflammatory therapies — reduced mortality rates in sepsis patients, improved HLA-DR expression on monocytes (a key marker of immune competence), and diminished the incidence of secondary infections. The authors identify Tα1 as a promising adjuvant therapy but note that the heterogeneity of sepsis makes it difficult to generalize results. They recommend that future trials specifically enroll immunosuppressed sepsis patients to better demonstrate efficacy.
Why it matters
Sepsis remains one of the leading causes of death in hospitals worldwide, and treatment options beyond antibiotics and supportive care are limited. An immune-modulating peptide that can restore the immune system's ability to fight infection — rather than just suppressing inflammation — could fill a critical gap in sepsis treatment, particularly for patients whose immune systems have become exhausted.
How the study worked
Systematic review of clinical studies on Tα1 treatment for sepsis and septic shock, drawn from both English and Chinese language databases. Studies evaluated Tα1 as monotherapy and in combination with anti-inflammatory agents. Outcomes assessed included mortality, immune function markers (HLA-DR on monocytes), and secondary infection rates.
What this study cannot tell us
Sepsis is extremely heterogeneous, making it difficult to generalize results across all patients. Most existing studies did not specifically select immunosuppressed patients, who are theoretically most likely to benefit. The review includes Chinese-language databases, where study quality and reporting standards may vary. Specific mortality reduction percentages and sample sizes were not detailed in the abstract. The review was published before larger randomized trials could provide definitive evidence.
How to read the evidence
This is a review of multiple clinical studies, including data from both English and Chinese databases. While the cumulative evidence is promising, the individual studies varied in size and quality, and large definitive randomized trials were lacking at the time of publication.
When this study was published
Published in 2018, this review summarizes the clinical evidence for Tα1 in sepsis up to that point. Interest in immune modulation for sepsis has grown significantly since, particularly after COVID-19.
The bigger picture
Sepsis treatment has historically focused on antibiotics and inflammation control, but many sepsis patients actually die from immune exhaustion — their immune systems shut down and can't fight infection. Thymosin alpha-1 addresses this by restoring immune function, representing a fundamentally different approach. This concept of immune restoration in sepsis has gained significant traction since COVID-19 highlighted similar immune dysfunction patterns.
Questions still open
- Would thymosin alpha-1 show clearer benefit in trials that specifically enroll sepsis patients with documented immunosuppression (low HLA-DR)?
- Is thymosin alpha-1 more effective when started early in sepsis or when immunosuppression is already established?
- How does thymosin alpha-1 compare to other immune-restoring approaches like IL-7 or anti-PD-1 in sepsis?
Common questions
How does thymosin alpha-1 help in sepsis?
Is thymosin alpha-1 approved for treating sepsis?
Read the original research
Thymosin alpha 1 treatment for patients with sepsis.
Expert opinion on biological therapy, 18(sup1), 71-76
Citation
Pei, Fei; Guan, Xiangdong; Wu, Jianfeng. (2018). Thymosin alpha 1 treatment for patients with sepsis.. Expert opinion on biological therapy, 18(sup1), 71-76. https://doi.org/10.1080/14712598.2018.1484104